Browsing Category
Pharma Industry News
4720 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
uniQure’s epilepsy data could test whether its gene therapy platform can expand beyond Huntington’s disease
Find out how uniQure’s AMT-260 epilepsy data could shape QURE stock sentiment and its broader neurology gene therapy strategy.
Abivax (NASDAQ: ABVX) obefazimod NDA path meets a safety debate the market is still pricing
Abivax (NASDAQ: ABVX) put up Rinvoq-like ulcerative colitis remission data and dropped 40 percent. The question is whether the malignancy debate sticks.
Could Context Therapeutics’ CLDN6 T cell engager strategy gain traction after ovarian cancer results?
Find out how Context Therapeutics’ CTIM-76 ovarian cancer data could shape its CLDN6 T cell engager strategy and investor outlook.
Why Pfizer’s CFO exit raises fresh questions about debt, deals and obesity strategy
Dave Denton’s departure leaves Pfizer searching for a permanent chief financial officer while it works to integrate major acquisitions, reduce leverage and prove that its oncology and obesity investments can replace declining mature-product revenue.
Aurobindo Pharma clears FTC hurdle for $250m Lannett acquisition
Aurobindo Pharma clears the FTC hurdle for its $250 million Lannett deal. Explore divestitures, US expansion, integration risks and stock outlook.
uniQure surges 78% as FDA clears accelerated approval path for its Huntington’s disease gene therapy
uniQure (QURE) surges 78 percent as FDA clears accelerated approval path for AMT-130 in Huntington's disease, with BLA filing due Q3 2026. Full analysis.
Moderna rallies into a landmark FDA advisory vote on its mRNA seasonal flu vaccine
Moderna (MRNA) rallies as an FDA advisory committee weighs its mRNA seasonal flu vaccine mFlusiva, the first such vote, with a decision due August 5. Full analysis.
Could pediatric anaphylaxis become the next growth opportunity for ALK Abelló’s EURneffy franchise?
Find out how EURneffy’s UK pediatric approval could strengthen ALK Abelló’s allergy strategy and challenge auto-injectors.
Why the RISE UP trial could become a defining test for Agios Pharmaceuticals’ mitapivat strategy
Find out how Agios Pharmaceuticals’ RISE UP trial could shape mitapivat’s sickle cell disease strategy and AGIO stock sentiment.
Biogen is paying up to $1bn for preclinical optionality. What does RayThera really add?
Biogen's $1 billion RayThera deal expands its immunology pipeline and raises fresh capital allocation questions. Read what BIIB investors should watch next.